For investors aiming to create a portfolio that produces steady passive income, a methodical screening process is necessary. One useful tactic includes looking for companies that provide a good dividend now and also have the fundamental financial soundness to maintain and raise those payments. This method frequently uses combined ratings that assess different parts of a company. A search for stocks with a high dividend rating, along with satisfactory marks for profitability and financial condition, can point to companies where the dividend is backed by a sound and effectively run business, instead of being a temporary feature of a company in trouble.
ELI LILLY & CO (NYSE:LLY) results from this type of screening process, offering a strong argument for dividend-oriented investors who also value expansion. The company’s basic profile, shown in its ChartMill Fundamental Analysis Report, displays a company performing well in many areas, with its dividend gaining from this general condition.
A Dividend Supported by Expansion
The base of a lasting dividend is a company's capacity to increase its earnings, and Lilly is very good here. This expansion directly aids the possibility for future dividend raises and keeps the payment easily manageable. The company's latest results have been impressive:
- Strong Recent Expansion: Revenue rose by 44.70% in the last year, while Earnings Per Share (EPS) increased by a notable 86.23%.
- Solid Past Performance: On average, EPS has grown 25.01% each year over recent years, showing steady performance.
- Good Future Expectations: Experts predict ongoing solid expansion, with EPS estimated to grow 20.51% on average each year in the near future.
This strong expansion path is important for dividend investors. It means the money used for shareholder payments comes from a growing amount of profits, lowering the chance the dividend will strain the company during weaker economic times.
Assessing the Dividend
While Lilly’s present dividend yield of 0.77% is low, particularly next to the wider S&P 500 average, the quality and direction of the payment are where the interest is for a patient investor. The ChartMill Dividend Rating of 7 shows a good overall evaluation built on several important points:
- Steady and Rising Payment: Lilly has paid and, notably, raised its dividend for at least ten straight years. The dividend has increased at an average yearly rate of 15.17% over this time, clearly exceeding inflation and delivering real income growth.
- High Security: The payout ratio is at a very low 26.09%. This shows the company uses just a fourth of its earnings for the dividend, leaving lots of space for putting money back into the business, purchases, and more dividend increases. The report states that earnings are rising quicker than the dividend, highlighting its security.
- Sector Position: In the active pharmaceuticals sector, Lilly’s dividend yield is higher than almost 90% of similar companies, showing a dedication to shareholder returns that is notable in its field.
The Supporting Factors: Profitability and Financial Condition
A high dividend rating is much more significant when it is supported by operational quality and a firm balance sheet. This is why searching for satisfactory profitability and condition ratings is a key part of the method. Lilly gets a top score of 9 for Profitability and a 6 for Financial Condition.
- Outstanding Profitability: The company has top-tier margins and returns. Its Return on Invested Capital (ROIC) of 31.47% and Profit Margin of 31.66% are higher than about 99% and 95% of industry peers, in order. This excellent efficiency means Lilly produces significant cash from its activities, which is the final source of steady dividend payments.
- Satisfactory Financial Condition with Points: The Condition rating of 6 shows a mostly good but varied situation. Good aspects contain a very strong Altman-Z score (8.09), pointing to low bankruptcy risk, and less debt compared to assets. However, investors should see the high Debt/Equity ratio (1.54) and a Debt to Free Cash Flow ratio of 7.13 years, which point to a notable use of debt financing. While these amounts are typical and even positive compared to many industry peers for expansion-focused pharma companies, they are an item to watch, particularly with higher interest rates.
Valuation Points
No review is finished without examining price. Lilly’s valuation numbers mirror its position as a top expansion leader. With a Price/Earnings (P/E) ratio of 38.29, the stock is expensive in simple terms. However, this higher price is explained by its fast expansion rate. The Price/Earnings to Growth (PEG) ratio, which includes expected earnings expansion, is viewed as low, indicating the valuation could be fair when future expansion is considered. Also, compared to its own industry, Lilly’s valuation on several numbers, including Forward P/E and Enterprise Value/EBITDA, is lower than most of its peers.
For investors who applied the "Best Dividend" screen to find ideas, ELI LILLY & CO (LLY) is a particular kind of find: a dividend expansion stock driven by impressive basic performance. It shows how a screening method centered on dividend quality, profitability, and condition can find companies where the dividend is a sign of total business soundness, not a replacement for it.
This screen is an initial step for more study. You can review the complete list of passing stocks and change the filters to fit your own needs by going to the Best Dividend Stocks screen.
Disclaimer: This article is for information only and is not financial advice, a suggestion, or an offer or request to buy or sell any securities. The information given is based on supplied data and should not be the only reason for any investment choice. Investing has risk, including the possible loss of principal. Always do your own research and think about talking with a qualified financial advisor before making any investment choices.